Shares of Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) dropped 4.8% during mid-day trading on Wednesday . The stock traded as low as $4.75 and last traded at $4.95. 1,726 shares were traded during trading, an increase of 433% from the average daily volume of 324 shares. The stock had previously closed at $5.20.
Starpharma Stock Down 4.8%
The business’s fifty day moving average is $4.83 and its 200 day moving average is $4.27.
About Starpharma
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
Further Reading
- Five stocks we like better than Starpharma
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
